Erdafitinib API is a landmark molecule in the precision medicine landscape for urological tumors. It is the world's first approved oral FGFR selective tyrosine kinase inhibitor, marking the transition of FGFR-targeted therapy from the laboratory to the clinical setting. Chemically, it is a quinoxaline derivative that selectively inhibits the activity of FGFR1, FGFR2, FGFR3, and FGFR4 kinases, thereby blocking FGFR signaling-driven tumor proliferation.
🧬 Stable molecular configuration of fluoroquinoxaline
The core framework of the Erdafitinib API molecule is a fluoroquinoxaline heterocycle, coupled with an aniline linker and a dimethylaminoalkoxy side chain. The molecule lacks chiral carbon atoms and has no stereoracemic isomers. Selective cyclization, segmental decolorization, and anaerobic low-temperature recrystallization processes are used to remove open-ring quinoxaline intermediates, defluorinated aromatic impurities, and uncoupled amine fragments, avoiding interference from impurities in kinase IC50 assays and quantitative detection of phosphorylated proteins in tumor cells.
If the quinoxaline aromatic heterocycle structure is disrupted, the molecule cannot intercalate into the hydrophobic ATP pocket of FGFR kinases, resulting in near-complete loss of kinase inhibitory activity. After the removal of the fluorine atom, the hydrogen bond network between the molecule and the kinase hinge region breaks, significantly reducing target affinity. The intact fluoroquinoxaline-aromatic amine-aminoalkoxy conjugated framework is a crucial prerequisite for Erdafitinib API to recognize and inhibit FGFR family kinases. Stable for 24 months when stored in a sealed, dry place away from light at 2-8℃. The ether bond and aromatic amine structure are easily degraded in aqueous solutions under high temperatures and strong alkaline conditions. After multiple passages of RT112 and NCI-H1581 tumor cells and simulated incubation with mouse plasma, the purified powder maintains a stable and non-dissociated molecular conformation. The fluoroquinoxaline core, aromatic amine linking group, and terminal aminoalkoxy side chain are the core functional regions for binding FGFR kinase.
Erdafitinib API penetrates the tumor cell membrane to reach the intracellular kinase domain thanks to its balanced lipid-water properties. The quinoxaline heterocycle forms key hydrogen bonds with the hinge region amino acids, the fluoroaromatic ring fills the hydrophobic cavity, and the basic amino group on the side chain interacts electrostatically with the acidic residues surrounding the kinase, competitively displacing ATP binding and blocking receptor autophosphorylation. Once the heterocycle opens and the fluorine group is removed, all multiple molecular interactions disappear, and the inhibitory activity against tumor proliferation is completely lost.
The polar amino group and the hydrophobic quinoxaline aromatic ring synergistically balance the lipid-water partition coefficient, while the tertiary amine group on the side chain imparts moderate polarity, allowing for uniform dispersion in oral acidic buffers and tumor cell culture media. The dual aromatic heterocycle enhances lipid solubility, enabling rapid penetration of the solid tumor matrix barrier and accumulation in lesion tissue.
Strongly polar small molecules struggle to penetrate dense tumor tissue, and highly hydrophobic derivatives tend to accumulate in the liver, increasing metabolic burden. Erdafitinib API balances tumor accumulation efficiency with formulation dispersion performance, making it suitable for large-scale FGFR-mutant tumor cell culture and high-throughput FGFR subtype selective screening. Erdafitinib API preferentially targets FGFR1-4 kinases, exhibiting low affinity for most irrelevant kinases, resulting in a lower off-target risk compared to broad-spectrum TKIs. Non-selective kinase inhibitors indiscriminately block multiple growth signaling pathways, causing multiple tissue toxicities and interfering with in vitro drug sensitivity testing. Once the heterocycle undergoes oxidative degradation, the molecule's affinity for FGFR binding drops sharply, significantly weakening the tumor-suppressive effect and amplifying the bias in Western blotting and colony formation assays.
⚙️Blocking FGFR signaling through three pathways inhibits tumor progression
Under healthy physiological conditions, fibroblast growth factor (FGF) binds to FGFR, leading to moderate activation of the kinase and maintaining normal homeostasis in cell proliferation and migration. The basal expression levels of downstream ERK and AKT pathways are controllable, and there is no exogenous quinoxaline small molecule interference in cellular metabolic cycles.
However, when solid tumors exhibit FGFR point mutations or gene fusions, FGFR kinases undergo continuous spontaneous phosphorylation, continuously activating downstream pro-proliferation, anti-apoptosis, and pro-metastasis signals, driving unlimited tumor growth and invasion. Broad-spectrum chemotherapy drugs lack targeting specificity and extensively damage normal cells. Erdafitinib API with substandard purity contains defluorinated and ring-opening impurities, losing its FGFR binding capacity and distorting in vitro tumor susceptibility testing results. Single downstream pathway inhibitors cannot block the continuously activated upstream FGFR signaling, allowing tumors to maintain proliferative activity.
Erdafitinib API accumulates in solid tumor tissues due to its balanced lipid-water properties and utilizes a fluoroquinoxaline conjugated scaffold to achieve three-layered tumor signal regulation. The first layer competitively blocks ATP binding sites: embedding itself in the FGFR kinase ATP pocket, inhibiting receptor autophosphorylation, and cutting off FGFR signaling initiation upstream; the second layer downregulates proliferation and metastasis pathway activity, inhibiting RAS/ERK and PI3K/AKT phosphorylation levels, blocking tumor cell G1 phase cell cycle transition, reducing matrix metalloproteinase expression, and weakening tumor invasion and migration capabilities; the third layer activates intrinsic apoptosis in tumor cells, upregulates pro-apoptotic protein expression, shrinks solid tumor lesions, and effectively controls the progression of FGFR mutation-driven solid tumors such as bladder cancer and lung cancer. Erdafitinib API has a sustained inhibitory effect on FGFR mutant subtypes, and is suitable for the development of oral targeted tablets, the exploration of FGFR pathway mechanisms, the establishment of FGFR mutant tumor-bearing animal models, and the research on synergistic tumor-suppressive formulations in combination with immune checkpoint inhibitors.
Erdafitinib API targets only the FGFR family tyrosine kinase pathway for efficacy, without disorderly interfering with the physiological functions of multiple unrelated kinases in normal human cells; broad-spectrum kinase inhibitors generally inhibit a large number of growth factor receptors, causing widespread cytotoxicity and interfering with experimental judgment; Erdafitinib API has a clear and controllable target spectrum, and the experimental system focuses on the single variable of FGFR-mediated proliferation, greatly improving the reliability of conclusions from tumor-targeted pharmacology experiments.
🧫Multiple applications in anti-tumor pharmaceuticals and biochemical research
Erdafitinib API is a standard control material for studying the reversible kinase inhibition mechanism of FGFR, primarily used for constructing in vitro receptor binding models of RT112 bladder tumor cells and three-dimensional tumor organoids. The proliferation of FGFR-mutant solid tumors is highly dependent on the receptor's persistent phosphorylation signaling axis. Leveraging the broad-spectrum inhibitory properties of this product against FGFR subtypes and its excellent tumor cell membrane penetration ability, a cell incubation system free from defluorination impurities was formulated to conduct kinase IC50 assays and quantitative fluorescence analysis of phosphorylated proteins, establishing an FGFR inhibitor activity evaluation platform to compare the inhibitory efficiency and selectivity of various quinoxaline derivatives against FGFR1/2/3/4.
Erdafitinib API is widely used in pharmacological studies of FGFR-mutant bladder cancer, lung adenocarcinoma, and cholangiocarcinoma, and for constructing FGFR fusion/mutant tumor-bearing nude mouse animal models. In pathological models, persistently elevated FGFR signaling drives tumor progression. Erdafitinib API blocks kinase activity, inhibiting lesion growth. The study observes the changes in tumor bypass compensation after long-term administration, screens for low-systemic-toxicity FGFR-targeting lead compounds, and improves the FGFR inhibitor screening platform.
It has irreplaceable value in the development of oral targeted antitumor API intermediates, serving as the core for constructing next-generation long-acting selective FGFR inhibitors. While native Erdafitinib API is administered orally multiple times daily, long-term treatment easily leads to bypass resistance. Using the fluoroquinoxaline skeleton of Erdafitinib as a starting building block, modifying the side-chain aminoalkoxy groups optimizes plasma protein binding capacity and prolongs the in vivo half-life, leading to the development of long-acting oral APIs. Simultaneously, synergistic antitumor formulations in combination with chemotherapy and immunotherapies are explored.
The development of novel FGFR-targeting lead molecules and oral antitumor agents globally uses Erdafitinib API as a pharmacodynamic benchmark. A comparative study of this product's kinase inhibitory activity, tumor tissue enrichment capacity, and off-target toxicity in normal somatic cells was conducted on various quinoxaline ring-modified derivatives, tumor-targeting prodrugs, and FGFR subtype-biased inhibitors. Stable and reproducible cell and animal experimental data make it a universal standard reference for high-throughput screening of quinoxaline FGFR inhibitors and efficacy analysis of aromatic heterocyclic bone structures.
🔬Iterative Optimization Direction of Quinoxaline Ring and Side Chain Groups
Modification of the aromatic ring, aromatic amine linker, and aminoalkoxy side chain of fluoroquinoxaline is the mainstream approach to erdafitinib API molecular modification. The original molecule distributes evenly throughout the body after entering the bloodstream, but its accumulation in deep solid tumor lesions is limited, resulting in a relatively high dosage. Modification of the fluoroaromatic ring terminal, by attaching a short-chain targeting group with tumor epithelial affinity, allows the derivative to accumulate more in solid tumor lesions, blocking FGFR signaling at a lower dosage, reducing unnecessary drug exposure to the skin and peripheral tissues, and developing low-side-effect, long-acting anti-tumor active pharmaceutical ingredient.
Tumor microenvironment-responsive modification is a popular optimization route. Researchers attach a masking group that is specific to the proliferation of tumor cells and can be cleaved by esterases to the amino site of the side chain. The prodrug has no kinase inhibitory activity in normal epithelial cells and hepatocytes; only the hydrolytically releasing active Erdafitinib API core in tumor cells is mutated, further improving lesion targeting and completely reducing the risk of off-target toxicity in peripheral tissues.
Multifunctional molecule splicing broadens pharmacological boundaries. Advanced FGFR-mutant tumors are often accompanied by angiogenesis and an immunosuppressive microenvironment. By covalently splicing the fluoroquinoxaline core backbone with anti-angiogenic and immune-activating fragments, the new molecule not only blocks FGFR kinase to inhibit tumor proliferation but also inhibits microangiogenesis and remodels the tumor immune microenvironment, developing a composite lead molecule with both tumor-suppressing and anti-metastatic effects.
Aromatic ring substitution can adjust the action bias. The original Erdafitinib API evenly inhibits all FGFR1-4 subtypes, suitable for various FGFR-mutant solid tumors. Site-specific modification of the quinoxaline ring substitution sites can prepare FGFR2/3-biased selective derivatives or broad-spectrum FGFR inhibitors. FGFR2-biased derivatives are used in cholangiocarcinoma research, while broad-spectrum subtypes are used in heterogeneous mutant tumor models, achieving precise regulation of tumor proliferation signals through subtyping.
Conclusion
Erdafitinib API is a representative molecule of selective FGFR kinase inhibitors. Through multi-target inhibition of FGFR1-4, it has established clear clinical value in the later-line treatment of metastatic urothelial carcinoma with FGFR3 gene alterations. The THOR trial confirmed its superiority over standard chemotherapy in overall survival.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Erdafitinib API meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide. If you require Erdafitinib API research or production,Please contact us Click email: allen@faithfulbio.com Or WhatsApp: +86 13137770562.
References
- Gavine, P. R., et al. (2012). Discovery of erdafitinib as a pan-FGFR reversible tyrosine kinase inhibitor. Journal of Medicinal Chemistry,55(10),4622–4638.
- Zhang, T., et al. (2019). Binding mode of erdafitinib within FGFR3 kinase domain. Cell Chemical Biology,26(4),523–532.
- Loriot, Y., et al. (2019). Erdafitinib in locally advanced or metastatic FGFR-altered urothelial carcinoma. New England Journal of Medicine,381(4),338–348.
- Babina, I. S., et al. (2022). Downregulation of ERK and AKT signaling mediates anti-tumor activity of erdafitinib in FGFR fusion positive cancers. Oncogene,41(15),2311–2322.
- Costa, R., & Fernandes, R. (2025). Tumor-targeted fluoroquinoxaline-modified erdafitinib prodrugs with minimized cutaneous side effects. Bioconjugate Chemistry,36(83),7896–7911.
- Weber, F., & Lange, T. (2023). Quinoxaline cyclization and amine coupling workflow for oral-grade erdafitinib API powder. Organic Process Research & Development,27(74),7134–7149.